Trial · NCT07352488
Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome
NCT07352488, Not applicable, Not yet recruiting, Henan University of Traditional Chinese Medicine
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome. Trials, record NCT07352488. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07352488
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Modified Shenling Baizhu Powder for Allergic Asthma With Spleen Deficiency and Dampness Accumulation Syndrome
- NCT number
- NCT07352488
- Status
- Not yet recruiting
- Phases
- Not applicable
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Henan University of Traditional Chinese Medicine
- Conditions
- Allergic Asthma
- Interventions
- Modified Shenling Baizhu Powder, Placebo, Budesonide and Formoterol Fumarate Powder for Inhalation
- First posted
- 2026-01-20
- Last updated
- 2026-01-20
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Asthma Control Test scores | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by Asthma Control Test. |
| Secondary | Acute exacerbation | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by the frequency and severity of acute exacerbation, and the time to first acute exacerbation. |
| Secondary | Asthma Control Questionnaire scores | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by Asthma Control Questionnaire. |
| Secondary | Asthma Quality of Life Questionnaire scores | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by Asthma Quality of Life Questionnaire. |
| Secondary | Pulmonary function | At baseline, week 8 of treatment, and week 12 of follow-up. | To be measured by pulmonary function test. |
| Secondary | Airway inflammatory markers | At baseline, week 8 of treatment, and week 12 of follow-up. | To be measured by fractional exhaled nitric oxide. |
| Secondary | Clinical symptom scores | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by clinical symptom questionnaire. |
| Secondary | Serum inflammatory markers | At baseline, week 4 and week 8 of treatment. | To be measured by blood eosinophil count, total serum IgE, IL-4, IL-5, TNF-α, etc. |
| Secondary | Immune markers | At baseline, week 4 or week 8 of treatment. | To be measured by CD4+, CD8+, CD4+/CD8+, Th17, and Treg. |
| Secondary | Use of controller medications | At baseline, week 4 and week 8 of treatment, and week 12 of follow-up. | To be measured by the usage of bronchodilator and glucocorticoid. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07352488
GET https://conductscience.org/api/trials/v1/NCT07352488/registered